Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
CytomX Therapeutics, Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
IPO Date: October 8, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $60.07M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.25 | 2.92%
Avg Daily Range (30 D): $0.03 | 5.39%
Avg Daily Range (90 D): $0.03 | 4.24%
Institutional Daily Volume
Avg Daily Volume: .71M
Avg Daily Volume (30 D): 1.08M
Avg Daily Volume (90 D): 1.36M
Trade Size
Avg Trade Size (Sh.): 182
Avg Trade Size (Sh.) (30 D): 466
Avg Trade Size (Sh.) (90 D): 432
Institutional Trades
Total Inst.Trades: 814
Avg Inst. Trade: $1.44M
Avg Inst. Trade (30 D): $1.1M
Avg Inst. Trade (90 D): $1.1M
Avg Inst. Trade Volume: .17M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.6M
Avg Closing Trade (30 D): $.52M
Avg Closing Trade (90 D): $.52M
Avg Closing Volume: 167.91K
       
News
Apr 28, 2025 @ 8:00 PM
CytomX Therapeutics Presents Preclinical Data for ...
Source: Cytomx Therapeutics
Mar 5, 2025 @ 1:00 PM
CytomX Therapeutics to Present at the Barclays 27t...
Source: N/A
Jun 17, 2024 @ 8:15 PM
CytomX Therapeutics Promotes Chris Ogden to Chief ...
Source: CytomX Therapeutics Inc.
May 22, 2024 @ 8:05 PM
CytomX Therapeutics to Present at the Jefferies Gl...
Source: CytomX Therapeutics Inc.
May 16, 2024 @ 8:15 PM
CytomX Therapeutics Announces New Employment Induc...
Source: CytomX Therapeutics Inc.
Financials
  TTM FY 2024 Q3 2024
Basic EPS
Diluted EPS
Revenue $ 138.1M $ 138.1M $ 33.43M
Gross Profit $ $ $
Net Income / Loss $ 31.87M $ 31.87M $ 5.74M
Operating Income / Loss $ 25M $ 25M $ 4.11M
Cost of Revenue $ $ $
Net Cash Flow $ 20.99M $ 20.99M $ -2.56M
PE Ratio